Health Canada grants OK to Auxilium/Actelion Dupuytren's drug
This article was originally published in Scrip
Executive Summary
Auxilium Pharmaceuticals and its partner Actelion Pharmaceuticals won approval from Health Canada for Xiaflex (collagenase clostridium histolyticum) as a treatment for adults with Dupuytren's contracture, a slowly progressive fibroproliferative disease, in which abnormal collagen deposits result in nodules and rope-like cords in the hand, eventually limiting finger movement.